Overexpression of MITF desensitizes BRAF-mutated melanoma cells to BRAFi, but MITF expression can be impaired following treatment with histone deacetylase inhibitors (HDACi), suggesting the potential benefit of a combination strategy with MAPK inhibitors. This evidence concerns the gene MITF and melanoma.